Congress extends ALS research funding, tightens safety reporting requirements

What it does

This bill extends the Accelerating Access to Critical Therapies for ALS Act through 2031, expanding the federal program that funds research grants for ALS treatments and therapies. It improves grant application requirements to ensure better data collection and safety reporting, broadens the program to include other rare neurodegenerative diseases, and adds new reporting requirements to track program effectiveness.

Why we flagged it

The bill's core function is to extend and improve a federal research-funding program for ALS and rare neurodegenerative diseases. It is a straightforward reauthorization with technical improvements to grant administration and reporting.

What the text implies

• Expansion to 'other rare neurodegenerative diseases' beyond ALS may broaden research funding scope without explicit appropriations language, potentially affecting budget allocation across multiple disease areas.
• New safety-data reporting requirements from ongoing clinical trials may increase administrative burden on grant recipients and sponsors, potentially affecting participation rates or grant application timelines.
• HHS report requirement (4 years post-enactment) creates accountability mechanism but also establishes a future legislative pressure point for program reauthorization or modification based on effectiveness findings.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill extends and strengthens a public health program that funds research into treatments for ALS and related rare neurodegenerative diseases, with no apparent restrictions on citizen rights or protections. The expanded data-collection and safety-reporting requirements improve transparency and accountability in how federal research dollars are spent.

Who stands to gain

• Academic medical centers and research institutions receiving ALS/neurodegenerative disease grants
• Pharmaceutical companies sponsoring investigational drug applications (through expanded access data

Named in the bill

Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79), FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce, GAO (Government Accountability Office)

Where it stands

15 cosponsors: 8 Democrats, 7 Republicans.

• Apr 30, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Apr 30, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Jun 17, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
• Aug 4, 2026 — Passed the Senate · Congress.gov: “Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $144,000 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Lisa Murkowski, the sponsor, reported $364,800 in PAC receipts in the 2026 cycle.

• Muscular Dystrophy Association, Inc. — $60,000 on 1 filing
• I Am Als — $30,000 on 1 filing
• The Als Association — $30,000 on 1 filing
• Nrx Pharmaceuticals Inc (formerly Known As Neurorx) — $24,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.